This trial is conducted in Europe. The aim of this trial is to develop a complement system targeted monoclonal antibody (mAb) to be used in treatment of subjects with chronic autoimmune diseases.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
Novo Nordisk Investigational Site
Groningen, Netherlands
Adverse events (AEs)
Time frame: Week 0-10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.